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Abstract
Our goal was to test the hypothesis that inter-individual genomic copy number variation in
control samples is a confounding factor in the non-invasive prenatal detection of fetal micro-
deletions via the sequence-based analysis of maternal plasma DNA. The database of geno-
mic variants (DGV) was used to determine the “Genomic Variants Frequency” (GVF) for
each 50kb region in the human genome. Whole genome sequencing of fifteen karyotypi-
cally normal maternal plasma and six CVS DNA controls samples was performed. The coef-
ficient of variation of relative read counts (cv.RTC) for these samples was determined for
each 50kb region. Maternal plasma from two pregnancies affected with a chromosome 5p
microdeletion was also sequenced, and analyzed using the GCREM algorithm. We found
strong correlation between high variance in read counts and GVF amongst controls. Conse-
quently we were unable to confirm the presence of the microdeletion via sequencing of
maternal plasma samples obtained from two sequential affected pregnancies. Caution
should be exercised when performing NIPT for microdeletions. It is vital to develop our
understanding of the factors that impact the sensitivity and specificity of these approaches.
In particular, benign copy number variation amongst controls is a major confounder, and
their effects should be corrected bioinformatically.
Introduction
Definitive prenatal diagnosis of genetic disease is currently performed via amniocentesis (AF)
or chorionic villus sampling (CVS). These are invasive procedures that carry an inherent risk
of miscarriage, fetal morbidity and parental anxiety[1–7]. Because of these risks, there has been
considerable interest in the development of non-invasive tests that can be performed on a
maternal blood sample in early gestation. One promising approach involves the analysis of
cell-free fetal DNA in maternal plasma, which can serve as a substrate for fetal genotyping[8].
These nucleic acids are thought to arise from apoptotic cells known as syncytiotrophoblastic
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microparticles that are shed from the placental villus into the uterine circulation[9–12]. Prog-
ress in this field has rapidly accelerated following the demonstration that whole genome
sequencing of maternal plasma DNA can be used for the non-invasive prenatal testing (NIPT)
of common aneuploidy, including successful translation of these methods into the clinical set-
ting[13–15].
Other chromosomal abnormalities such as microdeletions and microduplications occur
with approximately twice the frequency of aneuploidy[16, 17] and are, therefore, of major clini-
cal significance. Because of this, a number of methods for the diagnosis of microdeletions and
microdeletions have been developed. However, the majority of these anomalies are smaller in
size than the limits of detection of metaphase chromosome analysis. Thus, array comparative
genomic hybridization (aCGH) has emerged as a powerful tool for their high-resolution detec-
tion. Unfortuately, however, aCGHmust be performed utilizing AF or CVS.
In 2011 we demonstrated proof of concept that NIPT can be used for the non-invasive
detection of fetal microdeletions[18] and this has since been confirmed by at least three other
groups[19–21]. NIPT for microdeletions and microduplications is technically challenging,
with complications arising from the potential for false positive and false negative results, unan-
ticipated findings, and relatively high cost due to the amount of sequence data required. Fur-
thermore, our understanding of the utility of this approach in a broad sense is limited. In light
of this we tested the hypothesis that inter-individual variation in genomic copy number of con-
trol DNA samples is a confounding factor in the non-invasive prenatal detection of fetal micro-
deletions via the sequence-based analysis of maternal plasma DNA. We furthermore describe
the analysis of a 318.46kb interstitial chromosome 5p microdeletion and highlight a number of
key observations relating to NIPT in this context.
Materials and Methods
Human tissue samples
All patients provided written informed consent for use of their samples and clinical data. These
women received prenatal care at Magee-Womens Hospital within the years 2008–2013, and
were recruited from clinics and private practices. This protocol was approved by the University
of Pittsburgh Institutional Review Board (Protocol # IRB PRO07090033). A family presented
to Magee-Womens Hospital of UPMC at the Medical Genetics Department. The mother was
Gravida eight, Para three, and was seen at 19.0 weeks gestational age due to an increased risk
for Down Syndrome (1:42) and open neural tube defect (1:160) by multiple marker screen. An
amniocentesis was performed, and during ultrasound for the procedure, bilateral club feet and
an echogenic bowel were noted. Karyotype and FISH analysis from the amniocentesis revealed
46,XX. Comparative genomic hybridization (CGH)-based microarray analysis revealed a
318.46kb loss of 5p15.33 (Fig 1).
DNA extraction and sequencing
Plasma handling, DNA extraction and DNA sequencing were performed as previously
described[18].
Data analysis
Data were analyzed using the previously described GCREM approach[22]. Briefly, GCREM is a
linear mixed effect model for the read counts of different genomic regions in a DNA library,
where the GC content is an independent variable with a library specific random coefficient.
This linear mixed effect model is fitted using a set of libraries with known normal genomes to
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Fig 1. Comparative Genomic Hybridization Analysis of Affected Fetal Sample (First Pregnancy). Array
CGH profile showing an interstitial deletion in the short arm of chromosome 5. Top: Ideogram of chromosome
5. The deleted 5p15.33 region is indicated by a red rectangle. Below: A magnified view of the 5p subtelomeric
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estimate the region specific corrections for a list of genomic regions of interest. Then we apply
the corrections to the target library, and fit a linear model using only the regions that are
believed to be normal in the target library. We then predict the read count for the regions of
interest. By comparing the observed read counts with the predicted read counts, we can test if
the suspected regions indeed carry insertions or deletions.
Results
Summary statistics for sequencing libraries described herein are shown in S1 Table.
High variance in sequencing read counts amongst normal samples
strongly correlates with the frequency of genomic copy number variants
We hypothesized that the locus-specific variation of sequence read counts in libraries from
clinically normal samples caused by benign copy number variation will negatively affect the
performance of sequencing based copy number alteration (CNA) detection algorithms. Com-
mon to all sequencing based CNA detection algorithms, the test for the presence of a CNA is
dependent on three parameters: T: a measurement of the normalized read count of the region
of interest in the target sample; C: the average of the normalized read count in that region over
a group of normal control samples; S: the standard deviation of the normalized read count for
that group of normal control samples. The test statistic usually can be expressed as (T–C) ⁄ S.
With benign copy number variants in the group of normal control samples, we could see a
biased C and an inflated S, both of which will reduce the sensitivity and specificity of the CNA
detection algorithm.
To examine the relation between the variation of sequence read counts in libraries from
clinically normal samples and benign copy number variation, we selected fifteen maternal
plasma libraries from normal pregnancy samples that had been corrected for GC bias (S1 Fig).
We divided the human reference genome (GRCh37) into 50kb non-overlapping regions, and
calculated the relative read count (RTC) for each 50kb region, which is defined as the ratio of
the read count in a given 50kb region to the median of the read counts in all 50kb regions in
the whole genome (excluding regions with no aligned reads in all libraries). We also down-
loaded the Database for Genomic Variants (DGV)[23]. We first counted, for each 5kb region
in human genome, the number of structural variants reported in the DGV database overlap-
ping with that 5kb region (NDGV). Then we calculated, for each 50kb region, the Genomic
Variants Frequency (GVF) as the sum of NDGV over the ten 5kb regions inside the 50kb
region. Recall that GVF is the number of genomic variants observed in each 50kb region. It is
log2 transformed so that its distribution is closer to a Gaussian distribution. We found a strong
dependency between the coefficient of variation of the RTC (cv.RTC) across the fifteen libraries
for each 50kb region, and the risk of structural variation, measured as log2(GVF+1), for that
50kb region. For example, in each autosome, regions with high cv.RTC (> = 95% quantile of
the cv.RTC of all 50kb regions in that chromosome) have GVF values that are significantly
higher than regions with low cv.RTC (< 95% quantile) (Wilcoxon two sample test) (Figs 2A
and 3B, S2 Fig and S2A Table). On the other hand, the cv.RTC in regions with high GVF [log2
(GVF+1)> = 95% quantile of log2(GVF+1) of all 50kb regions in each chromosome] is
region. Positions are displayed according to GRCh37/hg19 Genome Browser. Shaded blue area indicates a
loss in DNA copy number detected by 22 oligonucleotide probes (blue dots), located in the interval
chr5:174,979–493,441 and encompassing an approximately 318 kb segment.
doi:10.1371/journal.pone.0153182.g001
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significantly higher than in regions with low GVF [log2(GVF+1)< 95% quantile] (Figs 2B and
3B, S2 Fig and S3A Table).
The high sample-to-sample variation observed in the fifteen plasma samples in certain
regions is not coincidental. We further analyzed the six unrelated control CVS obtained
between 10 and 13 weeks gestation, and found high sample-to-sample variation in the same
regions. More precisely, after correction for GC bias, for each of the 22 autosomes, we found
Fig 2. Boxplots of Genomic Variants Frequency (GVF) and coefficient of variation of Relative Read
Counts (cv.RTC). (A) Boxplots of log2(GVF+1) for regions with high cv.RTC (above 95% quantile of the cv.
RTC of all regions on chromosome 5) and low cv.RTC (below 95% quantile of cv.RTC) in maternal plasma
control libraries on chromosome 5 (representative). (B) Boxplot of cv.RTC of the maternal plasma control
libraries for regions with high GVF (above 95% quantile of the GVF of all regions on chromosome 5) and low
GVF (below 95% quantile of GVF) on chromosome 5 (representative).
doi:10.1371/journal.pone.0153182.g002
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that the cv.RTC of the 50kb regions in the CVS samples is significantly and positively corre-
lated with that in the plasma samples (t test, p values< 2.2e-16) (Fig 3A, S2 Fig), and shows a
strong dependency with the risk of structural variation (log2(GVF+1)) in the corresponding
regions (Fig 3C, S2 Fig, S2B and S3B Tables). We also explored other data preprocessing
Fig 3. Plots of Coefficient of Variation of the Relative Read Count (cv.RTC) for Chromosome 5. (A) The
cv.RTC of the 50kb regions in the CVS control libraries (y axis) against that in the maternal plasma control
libraries (x axis) for chromosome 5. (B) The cv.RTC of the 50kb regions in the plasma control libraries (y axis)
against the log2(GVF+1) of the 50kb regions reported in the DGV database (x axis) for chromosome 5. (C) The
cv.RTC of the 50kb regions in the CVS control libraries (y axis) against the log2(GVF+1) of the 50kb regions
reported in the DGV database (x axis) for chromosome 5. In all three plots, red dots represent 50kb regions
around the microdeletion (see Fig 3), black dots represent other 50kb regions in chromosome 5.
doi:10.1371/journal.pone.0153182.g003
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options, including deriving RTC from the read count data without GC content correction, as
well as using different parameters for the alignment, e.g., allowing mismatch vs not allowing
mismatch, and found similar results (Table 1). Interestingly, the CVS samples tend to have
smaller coefficients of variation than the plasma samples. Allowing mismatch and correcting
for GC content can also reduce the coefficient of variation, especially for the plasma samples
(Table 1).
Note that the samples included in the DGV database are not necessarily representative of
the population from which we collected the plasma and CVS control samples. This makes the
strong correlation between the cv.RTC of the plasma and CVS control libraries on the one side,
and the GVF derived from the DGV database on the other side even more remarkable.
The effect of high variance of read counts on the ability to detect a fetal
microdeletion by sequencing maternal plasma DNA
The effect of high variance of the read counts on the non-invasive prenatal diagnosis of fetal
microdeletion is best illustrated by the following case study. A plasma DNA sample (PL741)
from a mother carrying a fetus with a confirmed paternally inherited ~318.46Kb interstitial
deletion on chromosome 5 between 174,979–493,441 (hg19) (Fig 1) was obtained at 32.4 weeks
gestation and subjected to paired end (100 x 2) whole genome sequencing on the Illumina
HiSeq 2000.
We first tested for the presence of the microdeletion in PL741 using the fifteen confirmed
karyotypically normal control plasma samples discussed above. As shown in Fig 4A, there was
no clear evidence that the PL741 microdeletion was detectable using this approach.
We also sequenced DNA from fetal amniocytes (C741), maternal leukocytes (M741), and a
paternal sample (Pat741) obtained from the affected PL741 pregnancy. We used the six karyo-
typically normal CVS tissue samples discussed above as controls, so that the pure maternal,
paternal, and fetal samples from pregnancy PL741 could be compared with “like”, high molec-
ular weight nuclear DNA, controls rather than plasma-derived DNA. As shown in Fig 4B, we
were clearly able to detect copy number loss in the confirmed 318.46Kb deleted region in the
pure fetal (C741). As expected, consistent with paternal transmission of this mutation, we
found in the paternal sample (Pat741) an almost identical pattern of copy number loss (Fig 4E)
to the pure fetal sample, but no evidence of copy number loss in the maternal leukocyte sample
(M741) (Fig 4C).
In order to confirm that fetal DNA in the PL741 plasma was indeed at a detectable level and
within the expected range of sensitivity of our assay we analyzed the sequencing data from the
PL741 plasma sample to determine the percentage of fetal genome equivalents. We used a
Table 1. The 25%, 50%, 75%, and 97.5% quantiles of the coefficient of variation of RTC in chromosome 5. For CVS, the coefficient of variations were
estimated from 6 libraries. For maternal plasma, the coefficient of variations were estimated from fifteen libraries unrelated to the CVS samples.
Sample GC correction Allow mismatch 25.00% 50.00% 75.00% 97.50%
CVS Yes No 0.0286 0.0370 0.0471 0.0784
CVS Yes Yes 0.0231 0.0297 0.0369 0.0632
CVS No No 0.0293 0.0381 0.0487 0.0871
CVS No Yes 0.0239 0.0307 0.0386 0.0738
Plasma Yes No 0.0383 0.0464 0.0563 0.1131
Plasma Yes Yes 0.0324 0.0391 0.0475 0.1027
Plasma No No 0.0463 0.0554 0.0676 0.1214
Plasma No Yes 0.0402 0.0481 0.0593 0.1151
doi:10.1371/journal.pone.0153182.t001
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Fig 4. GCREM Tests of Chromosome 5 Microdeletion. (A) GCREM test of the maternal plasma library
(data is from 1 of a total of 13 HiSeq 2000 lanes) from the first pregnancy. (B) GCREM test of the fetal
amniocyte library from the first pregnancy. (C) GCREM test of the maternal genomic libraries (data is from 4
HiSeq 2000 lanes) from the first pregnancy. (D) GCREM test of the maternal plasma library from the second
pregnancy (PL1694). (E) GCREM test of the paternal genomic (leukocyte-derived) library (pat741). For all
plots, Y axis is the difference between observed RTC and expected RTC. Positive values mean potential
gain, negative values mean potential loss. X axis is the position on the chromosome. Each horizontal bar
represents a 150kb region. Dotted lines are standard deviation of the expected RTC.
doi:10.1371/journal.pone.0153182.g004
Challenges of NIPT
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method that we developed for this purpose, which is a modification of our previously published
work[24]. Briefly, we identified SNPs that are homozygous in the maternal sample and hetero-
zygous in the fetal sample. The frequency of the paternally inherited allele to the maternal allele
then is half of the fetal frequency. Using generalized linear model, our estimation of the fetal
DNA frequency in the first plasma data is approximately 15%, which is well within the
expected normal range for such samples.
Eventually, we were able to obtain a chorionic villus sample from a subsequent pregnancy
involving the same family. Again, microarray analysis was performed (not shown) and the
same chromosome 5 microdeletion was identified. A plasma sample (PL1694) was obtained at
11 weeks. GCREM analysis of the maternal plasma (PL1694) from the second pregnancy
showed the same results as those (PL741) from the first pregnancy in that the 318.46Kb dele-
tion was not detected (Fig 4D).
A close examination of the fifteen plasma and six CVS control samples showed that, despite
corrected for GC bias (S1 Fig), the read counts of the regions of interest in these controls dis-
played extremely high sample-to-sample variation. We found that, across the control samples,
the coefficient of variation of the RTC in the regions of interest are much higher than other
regions of chromosome 5. For example, for the RTC derived from the GC corrected read count
data, the lower quartile, median, upper quartile, and 97.5% of the coefficient of variation for all
chromosome 5 regions are 0.038, 0.046, 0.056, and 0.113 respectively. However, among the 31
regions of interest (located in chr5:10000–1710000), 17 of them have a coefficient of variation
greater than the upper quartile, and 11 of them have a coefficient of variation greater than the
97.5% quantile.
Discussion
We present an analysis of sequenced normal maternal plasma and CVS DNA samples that
were used as controls in the context of NIPT for fetal microdeletions and microduplications.
We found that in some genomic regions, these control samples exhibited extremely high vari-
ance, as observed in both the CVS and plasma control data. The high variance in these regions
is not incidental, because the distribution of high variance regions across the whole genome is
strikingly similar between the fifteen maternal plasma libraries and the six unrelated CVS
libraries. More importantly, we found a strong correlation between the distribution of the high
variance regions in both the plasma and CVS libraries and the distribution of reported struc-
tural variation in the DGV database. Statistical tests showed that the RTCs of the regions where
the DGV database reported a high degree of structural variation have significantly higher coef-
ficient of variation than the regions with fewer reported structural variations.
The presence of regions with high risk of structural variations in the control libraries repre-
sents a serious challenge to the application of NIPT technologies for the detection of microdele-
tions and microduplications. While the number of high-risk regions may be small, the chance
that a structural variation will occur in such regions is high. Using the data from the DGV data-
base, about 7% of the 50kb regions were found to have a GVF of 2000 or higher, but these
account for 70% of total GVF reported in the database.
To illustrate, we used those fifteen plasma samples as controls to investigate a maternal
plasma sample with microdeletion on the short arm of chromosome 5. Because of the
extremely high variance in the control samples over this region, we were unable to detect this
via non-invasive methods, despite the comprehensive analysis of plasma DNA using proven
statistical tools.
Based on the results presented above, in order to apply NIPT technology to the detection of
a broad spectrum of microdeletions and microduplications, the influence of structural
Challenges of NIPT
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variations in the control plasma samples would need to be mitigated. To do this, we would ide-
ally need to obtain a subset of plasma samples with no structural variants, at least over the
regions of interest, so that these samples could serve as the controls for the microdeletion and
microduplication tests. However, given the diversity of the human genome, it is difficult, if not
impossible, to find samples containing sequence over a large region that is identical to the ref-
erence genome. Instead, we recommend correcting the effect of structural variants on a given
maternal plasma-sequencing library such that a corrected library will have a read count distri-
bution over the regions of interest similar to that of a sample of the reference genome.
Briefly, this would require matched maternal plasma (MP), maternal blood cells (MBC),
and CVS samples. By deep sequencing of the maternal and fetal genomes, preferably enriched
over the regions of interest, we can assemble the maternal and fetal genomes against the refer-
ence genome. Importantly, because the mother and the fetus share a copy of chromosome sets,
we can derive the haplotype information for both the mother and the fetus over the regions of
interest. By sequencing the maternal plasma samples, we can also estimate the percentage of
fetal DNA in maternal plasma[24]. Then we can determine either analytically or by simulation
how the structural variants in the maternal and fetal genomes affect, in maternal plasma
sequencing libraries, the distribution of reads over the reference genome. In turn we can correct
the maternal plasma libraries to remove these effects so that the read distribution in the cor-
rected libraries would be similar to that from libraries generated from the reference genome.
The availability of control plasma samples with corrected read counts over the regions of inter-
est will greatly increase the range of application of the NIPT technology from regions with low
risk of copy number variation to regions of higher risk of copy number variation, so that it can
be offered as a viable and risk-free alternative to invasive diagnostic procedures.
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